Join us from 27-28th Oct for the ISPE Annual Meeting & Expo 2025 in Charlotte, NC, US
Join us from 27-28th Oct for the ISPE Annual Meeting & Expo 2025 in Charlotte, NC, US
Experience Leucine AI .
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System /
Calibration Management
Calibration Management
View Detailed Analysis

Analytics Overview

38
Form 483s Issued
7
483s converted to WL
42
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
05 Sep 2025
Aurobindo Pharma Ltd.
Drugs
27 May 2025
Samsung Biologics Co., Ltd.
Drugs
10 Apr 2025
Aurolige Pharma LLC
Drugs
06 Jan 2025
Suzhou Suncadia Biopharmaceuticals Co. Ltd.
Drugs
19 Nov 2024
Dr. Reddy's Laboratories Limited (Unit II)
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Teresa I Navas
3
0
José E Melendez
3
0
Edmund F Mrak
3
1
Gavin T Cua
2
0
Jamirya S Weatherly
2
0
TITLE/ COMPANY Issue Date Status Details
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Aurobindo Pharma Ltd.
05 Sep 2025 Normal Justification: The calibration process failed due to inappropriate equipment usage, affecting measurement accuracy.
Excerpt: Calibration was performed using a scale that did not have the sensitivity (nearest thousandths) to measure 10 microliters (uL) ± 0.12 (nearest hundredths) accurately and precisely.
View Details
Your firm failed to appropriately install and qualify equipment used in the production of Active Pharmaceutical Ingredients
Not available
01 Aug 2025 Normal Justification: Calibration Management is central as calibration certificates for critical testing equipment were expired, affecting product quality.
Excerpt: The high-performance liquid chromatography (HPLC) system used for the analysis of API purity was observed to have calibration certificates expired.
View Details
Procedures and controls utilized within the Quality Control (QC) Laboratory in support of drug substance release and (b) (4) testing are deficient.
Samsung Biologics Co., Ltd.
27 May 2025 Normal Justification: Equipment error linked to outdated calibration standards impacted test results, indicating Calibration Management issues.
Excerpt: Delays in requalification of the reference standard and equipment error.
View Details
Routine calibration of automatic equipment is not performed according to a written program designed to assure proper performance
Aurolige Pharma LLC
10 Apr 2025 Normal Justification: The issue directly relates to how the calibration of the equipment is managed, affecting measurement accuracy.
Excerpt: The balance with Equipment Id. MF-BS-11 is not calibrated within the range of use.
View Details
Automatic or electronic equipment, including computers or related systems, are not routinely calibrated, inspected, or checked according to written programs
Suzhou Suncadia Biopharmaceuticals Co. Ltd.
06 Jan 2025 Normal Justification: Calibration Management directly relates to the failure to routinely calibrate and verify electronic equipment for proper performance.
Excerpt: Software settings for (b)(4) Non-viable Particle (NVP) monitoring systems were not verified to ensure proper performance after system upgrades.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.

Calibration Management

Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

Written By
Vivek Gera
Reading Time
8
Minutes

Calibration Management

Overview

38
Form 483s Issued
7
483s converted to WL
42
Total Observation
Form 483s Issued
+74 from last period

Recent Form 483s & Warning Letters

Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
05 Sep 2025
Aurobindo Pharma Ltd.
Drugs
27 May 2025
Samsung Biologics Co., Ltd.
Drugs
10 Apr 2025
Aurolige Pharma LLC
Drugs
06 Jan 2025
Suzhou Suncadia Biopharmaceuticals Co. Ltd.
Drugs
19 Nov 2024
Dr. Reddy's Laboratories Limited (Unit II)
Drugs

Top FDA Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Teresa I Navas
3
0
José E Melendez
3
0
Edmund F Mrak
3
1
Gavin T Cua
2
0
Jamirya S Weatherly
2
0

Key Observations

TITLE/ COMPANY Issue Date Status Details
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Aurobindo Pharma Ltd.
05 Sep 2025 Normal Justification: The calibration process failed due to inappropriate equipment usage, affecting measurement accuracy.
Excerpt: Calibration was performed using a scale that did not have the sensitivity (nearest thousandths) to measure 10 microliters (uL) ± 0.12 (nearest hundredths) accurately and precisely.
View Details
Your firm failed to appropriately install and qualify equipment used in the production of Active Pharmaceutical Ingredients
Not available
01 Aug 2025 Normal Justification: Calibration Management is central as calibration certificates for critical testing equipment were expired, affecting product quality.
Excerpt: The high-performance liquid chromatography (HPLC) system used for the analysis of API purity was observed to have calibration certificates expired.
View Details
Procedures and controls utilized within the Quality Control (QC) Laboratory in support of drug substance release and (b) (4) testing are deficient.
Samsung Biologics Co., Ltd.
27 May 2025 Normal Justification: Equipment error linked to outdated calibration standards impacted test results, indicating Calibration Management issues.
Excerpt: Delays in requalification of the reference standard and equipment error.
View Details
Routine calibration of automatic equipment is not performed according to a written program designed to assure proper performance
Aurolige Pharma LLC
10 Apr 2025 Normal Justification: The issue directly relates to how the calibration of the equipment is managed, affecting measurement accuracy.
Excerpt: The balance with Equipment Id. MF-BS-11 is not calibrated within the range of use.
View Details
Automatic or electronic equipment, including computers or related systems, are not routinely calibrated, inspected, or checked according to written programs
Suzhou Suncadia Biopharmaceuticals Co. Ltd.
06 Jan 2025 Normal Justification: Calibration Management directly relates to the failure to routinely calibrate and verify electronic equipment for proper performance.
Excerpt: Software settings for (b)(4) Non-viable Particle (NVP) monitoring systems were not verified to ensure proper performance after system upgrades.
View Details

Frequently Asked Questions

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5
Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Block quote

Ordered list

  1. Item 1
  2. Item 2
  3. Item 3

Unordered list

  • Item A
  • Item B
  • Item C

Text link

Bold text

Emphasis

Superscript

Subscript

Experience Leucine AI Powered pharma manufacturing
300+ pharma facilities worldwide use Leucine to stay compliant. Talk to one of our expert consultants at Leucine to learn how.
Related Resources

View and learn more about FDA Inspections
with our comprehensive list of resources